Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTDSP1 | Q9GZU7 | 3/20 | 0.41 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL28141714 | 0.85 | CTDSP1 (0.46) | CTDSP1APOBEC3AAPOBEC3GSIGMAR1LMNA | |
| SCHEMBL28083324 | 0.84 | CTDSP1 (0.50) | CTDSP1APOBEC3AAPOBEC3GSIGMAR1LMNA | |
| SCHEMBL1031219 | 0.84 | CTDSP1 (0.50) | CTDSP1APOBEC3AAPOBEC3GSIGMAR1LMNA | |
| SCHEMBL27346088 | 0.82 | CTDSP1 (0.48) | CTDSP1APOBEC3AAPOBEC3GSIGMAR1LMNA | |
| SCHEMBL27687791 | 0.82 | CTDSP1 (0.48) | CTDSP1APOBEC3AAPOBEC3GSIGMAR1LMNA | |
| Water SCHEMBL27578450 | 0.82 | CTDSP1 (0.48) | CTDSP1APOBEC3AAPOBEC3GSIGMAR1LMNA | |
| Acetic Acid SCHEMBL27819449 | 0.81 | CTDSP1 (0.41) | CTDSP1APOBEC3AAPOBEC3GSIGMAR1LMNA | |
| Dimethylamine SCHEMBL28128735 | 0.79 | CTDSP1 (0.46) | CTDSP1APOBEC3AAPOBEC3GSIGMAR1LMNA | |
| SCHEMBL28198757 | 0.77 | CTDSP1 (0.45) | CTDSP1APOBEC3AAPOBEC3GSIGMAR1LMNA | |
| Benzene SCHEMBL27563818 | 0.77 | CTDSP1 (0.45) | CTDSP1APOBEC3AAPOBEC3GSIGMAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680720-A1 | OPTIMIZED PRODUCTION OF BRANCH POINT COMPOUNDS AND DERIVATIVES USING ALTERNATIVE ISOPENTENYL DIPHOSPHATE-SUPPLYING PATHWAYS | EvodiaBio ApS (DK) | 2026-01-21 | — | — | EP | claimed |
| US-12529077-B2 | Production of geranyl diphosphate-derived compounds | Københavns Universitet (DK) | 2026-01-20 | — | — | US | claimed |
| WO-2024189183-A1 | OPTIMIZED PRODUCTION OF BRANCH POINT COMPOUNDS AND DERIVATIVES USING ALTERNATIVE ISOPENTENYL DIPHOSPHATE-SUPPLYING PATHWAYS | EVODIABIO APS (DK) | 2024-09-19 | — | — | WO | claimed |
| US-20230159960-A1 | Production Of Geranyl Diphosphate-Derived Compounds | KOBENHAVNS UNIVERSITET (DK) | 2023-05-25 | — | — | US | claimed |
| EP-4133063-A1 | PRODUCTION OF GERANYL DIPHOSPHATE-DERIVED COMPOUNDS | Københavns Universitet (DK) | 2023-02-15 | — | — | EP | claimed |
| CN-115698272-A | Production of geranyl diphosphate derived compounds | 哥本哈根大学 | 2023-02-03 | — | — | CN | claimed |
| US-20220218639-A1 | TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2022-07-14 | — | — | US | claimed |
| CN-114561308-A | Recombinant yeast engineering bacterium for producing D-borneol | 四川弘合生物科技有限公司 | 2022-05-31 | — | — | CN | claimed |
| US-20040072311-A1 | Production of cyclic terpenoids | E.I. DU PONT DE NEMOURS AND COMPANY | 2004-04-15 | — | — | US | claimed |
| EP-1313841-A2 | PRODUCTION OF CYCLIC TERPENOIDS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2003-05-28 | — | — | EP | claimed |
| US-20020142408-A1 | Production of cyclic terpenoids | E.I. DU PONT DE NEMOURS AND COMPANY | 2002-10-03 | — | — | US | claimed |
| WO-2002020815-A2 | PRODUCTION OF CYCLIC TERPENOIDS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2002-03-14 | — | — | WO | claimed |
| US-12577572-B2 | Compositions, systems, and methods for high level expression of recombinant protein | DUKE UNIVERSITY (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4680720-A1 | OPTIMIZED PRODUCTION OF BRANCH POINT COMPOUNDS AND DERIVATIVES USING ALTERNATIVE ISOPENTENYL DIPHOSPHATE-SUPPLYING PATHWAYS | EvodiaBio ApS (DK) | 2026-01-21 | — | — | EP | disclosed |
| US-12529077-B2 | Production of geranyl diphosphate-derived compounds | Københavns Universitet (DK) | 2026-01-20 | — | — | US | disclosed |
| US-20250312524-A1 | METHODS OF AMELIORATION OF CEREBROSPINAL FLUID AND DEVICES AND SYSTEMS THEREFOR | ENCLEAR THERAPIES, INC. | 2025-10-09 | — | — | US | disclosed |
| EP-1017788-A4 | MONOTERPENE SYNTHASES FROM COMMON SAGE ($i(SALVIA OFFICINALIS)) | UNIV WASHINGTON (US) | 2005-03-16 | — | — | EP | disclosed |
| EP-1017788-A1 | MONOTERPENE SYNTHASES FROM COMMON SAGE ($i(SALVIA OFFICINALIS)) | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2000-07-12 | — | — | EP | disclosed |
| US-5891697-A | Monoterpene synthases from common sage (Salvia officinalis) | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION | 1999-04-06 | — | — | US | disclosed |
| WO-1999015624-A1 | MONOTERPENE SYNTHASES FROM COMMON SAGE (SALVIA OFFICINALIS) | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12529077-B2 | Production of geranyl diphosphate-derived compounds | GGPS1, OGA, GBA3 | CTDSP1 1560/4885APOBEC3A 1352/4885APOBEC3G 2567/4885 |
| US-12577572-B2 | Compositions, systems, and methods for high level expression of recombinant protein | SLC34A2, SLC34A1, PURB | CTDSP1 2633/4885APOBEC3A 1734/4885APOBEC3G 3113/4885 |
| US-20220218639-A1 | TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS | PLAT, PLG, PLAUR | CTDSP1 897/4885APOBEC3A 3427/4885APOBEC3G 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.